论文部分内容阅读
目的观察通心络联合瑞舒伐他汀治疗2型糖尿病合并颈动脉粥样硬化对患者血清细胞因子的影响。方法将2型糖尿病合并颈动脉粥样硬化患者205例随机分为观察组103例和对照组102例,在糖尿病基础治疗的同时,对照组给予瑞舒伐他汀治疗;观察组在对照组治疗的基础上给予通心络胶囊治疗,2组疗程均为3个月。比较2组患者治疗前后血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子α(TNF-α)水平的变化。结果观察组总有效率为94.17%显著高于对照组的84.31%,差异有统计学意义(P<0.05);治疗后2组患者血清IL-6、TNF-α和hs-CRP水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。结论通心络联合瑞舒伐他汀治疗2型糖尿病合并颈动脉粥样硬化患者疗效显著,在调节血脂代谢紊乱、减轻免疫炎性反应反面均具有较好的抗动脉粥样硬化作用。
Objective To observe the effect of Tongxinluo combined with rosuvastatin on serum cytokines in type 2 diabetic patients with carotid atherosclerosis. Methods A total of 205 patients with type 2 diabetes mellitus and atherosclerosis were randomly divided into observation group (n = 103) and control group (n = 102). The patients in the control group were treated with rosuvastatin, while the patients in the control group Tongxinluo capsule was given on the basis of treatment, and the two courses of treatment were 3 months. The changes of serum hs-CRP, IL-6 and TNF-α before and after treatment were compared between the two groups. Results The total effective rate in the observation group was 94.17%, which was significantly higher than that in the control group (84.31%), the difference was statistically significant (P <0.05). The levels of IL-6, TNF-α and hs- (P <0.05), and the observation group was lower than the control group (P <0.05). Conclusion Tongxinluo combined with rosuvastatin treatment of patients with type 2 diabetes mellitus and carotid atherosclerosis significant effect in the regulation of dyslipidemia, reduce immune anti-inflammatory side have better anti-atherosclerotic effect.